Technical Note
Free Access
Sequential immunotyping and genotyping of tumor cells in bone marrow of cancer patients: A model study
P. Müller,
D. Hempel,
D. Oruzio,
S. Ehnle, K. Kolloch,
G. Schlimok,
Corresponding Author
P. Müller
Medical Clinic II, Zentralklinikum, Augsburg, Germany
Medizinische Klinik, Zentralklinikum Augsburg, Stenglinstr., D-86156 Augsburg, GermanySearch for more papers by this authorD. Hempel
Medical Clinic II, Zentralklinikum, Augsburg, Germany
Search for more papers by this authorD. Oruzio
Medical Clinic II, Zentralklinikum, Augsburg, Germany
Search for more papers by this authorK. Kolloch
Medical Clinic II, Zentralklinikum, Augsburg, Germany
Search for more papers by this authorG. Schlimok
Medical Clinic II, Zentralklinikum, Augsburg, Germany
Search for more papers by this authorP. Müller,
D. Hempel,
D. Oruzio,
S. Ehnle, K. Kolloch,
G. Schlimok,
Corresponding Author
P. Müller
Medical Clinic II, Zentralklinikum, Augsburg, Germany
Medizinische Klinik, Zentralklinikum Augsburg, Stenglinstr., D-86156 Augsburg, GermanySearch for more papers by this authorD. Hempel
Medical Clinic II, Zentralklinikum, Augsburg, Germany
Search for more papers by this authorD. Oruzio
Medical Clinic II, Zentralklinikum, Augsburg, Germany
Search for more papers by this authorK. Kolloch
Medical Clinic II, Zentralklinikum, Augsburg, Germany
Search for more papers by this authorG. Schlimok
Medical Clinic II, Zentralklinikum, Augsburg, Germany
Search for more papers by this authorFirst published: 12 December 1998
Citations: 4
Abstract
Epithelial cells can be detected in bone marrow or peripheral stem cell preparations of patients with various kinds of cancer and their presence in bone marrow is of prognostic significance. Characterization of these cells has been hampered by their low frequency. Here we present a method that may allow sequential immunophenotyping and genotyping of epithelial cells in bone marrow. To simulate in vivo situations, cells from the colon cancer cell line HT29 were seeded into bone marrow and were first detected by the Fab fragment of the A45-B/B3 anticytokeratin antibody. Expression of Ki67, p53, Her-2/neu (c-erbB2), and 17–1A could be detected on A45-B/B3-stained cells by immunofluorescence using a fluorescein-labeled anti-mouse immunoglobulin specific for the Fc part of mouse immunoglobulins. Reactivity for all antigens except for Ki67 persisted after A45-B/B3 labeling even when a scoring step for the presence of epithelial cells was performed before proceeding with the immunophenotyping. After immunophenotyping, numerical chromosomal aberrations and amplifications of the Her-2/neu oncogene could be assessed by fluorescence in situ hybridization in the same A45-B/B3-stained cells. This combination of immunophenotyping and genotyping may help in establishing the role of epithelial cells in bone marrow or peripheral stem cell harvests for tumor relapse and formation of metastases. Cytometry 33:492–497, 1998. © 1998 Wiley-Liss, Inc.
Literature Cited
- 1 American Type Culture Collection, Catalogue of cell lines and hybridomas, 7th ed. Rockville, MD, 1992
- 2 Cote RJ, Rosen PP, Lesser LM, Old LJ, Osborne MP: Prediction of early relaps in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 9: 1749–1756, 1991.
- 3 Cattoretti G, Becker MHG, Key G, Duchrow M, Schluter C, Galle J, Gerdes J Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB3) detect proliferating cells in microwave processed formalin-fixed paraffin section. J Pathol 168: 357–363, 1992.
- 4
De Witte HH,
Foekens JA,
Lennerstrand J,
Smid M,
Look MP,
Klun JGM,
Benraad TJ,
Berns EMJJ:
Prognostic significance of TP53 accumulation in human primary breast cancer: Comparison between a rapid quantitative immunoassay and SSCP analysis.
Int J Cancer
69:
125–130,
1996.
10.1002/(SICI)1097-0215(19960422)69:2<125::AID-IJC10>3.0.CO;2-8 CAS PubMed Web of Science® Google Scholar
- 5 Diel IJ, Kaufmann M, Costa SD, Holle R, von Minckwitz G, Solomayer EF, Kaul S, Bastert G: Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status. J Natl Cancer Inst 88: 1652–64, 1996.
- 6 Dougall WC, Qian X, Peterson NC, Miller MJ, Samanta A, Greene MI: The neu oncogene: Signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene 9: 2109–2123, 1994.
- 7 Garcia-Marco J, Matutes E, Morilla R, Ellis J, Oscier D, Fantes J, Catovsky D, Price CM: Trisomy 12 in B-cell chronic lymphocytic leukemia: Assessment of lineage restriction by simultaneous analysis of immunophenotype and genotype in interphase cells by fluorescence in situ hybridization. Br J Haematol 87: 44–50, 1994.
- 8 Göttlinger HG, Funke I, Johnson JP, Gokel JM, Riethmüller G: The epithelial cell surface antigen 17–1A, a target for antibody-mediated tumour therapy: Its biochemical nature, tissue distribution and recognition by different monoconal antibodies. Int J Cancer 38: 47–53, 1986.
- 9 Jauch K-W, Heiss MM, Gruetzner U, Funke I, Pantel K, Babic R, Eissner H-J, Riethmüller G, Schildberg F-W: Prognostic significance of bone marrow micrometastases in patients with gastric cancer. J Clin Oncol 14: 1810–1817, 1996.
- 10 Johnson GD, Nogueria JGM: A simple method of reducing the fading of immunofluorescence during microscopy. J Immunol Methods 43: 349–350, 1981.
- 11 Kallioniemi O-P, Kallioniemi A, Kurisu W, Thor A, Chen L-C, Smith HS, Waldman FM, Pinkel D, Gray JW: ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA 89: 5321–5325, 1992.
- 12 Knuutila S, Nyland SJ, Wessman M, Larramendy ML: Analysis of genotype and phenotype on the same interphase or mitotic cell. A manual of MAC (morphology antibody chromosomes) methodology. Cancer Genet Cytogenet 72: 1–15, 1994.
- 13 Lindemann F, Schlimok G, Dirschedl P, Witte J, Riethmüller G: Prognostic significance of micrometastatic tumor cells in bone marrow of colorectal cancer patients. Lancet 340: 685–689, 1992.
- 14
Little VR,
Lockett SJ,
Pallavicini MG:
Genotype/phenotype analysis of low frequency tumor cells using computerized image microscopy.
Cytometry
23:
344–349,
1996.
10.1002/(SICI)1097-0320(19960401)23:4<344::AID-CYTO11>3.0.CO;2-T CAS PubMed Web of Science® Google Scholar
- 15 Mansi JL, Berger U, McDonell T, Pople A, Rayter Z, Gazet JC, Coombes RC: The fate of bone marrow micrometastases in patients with primary breast cancer. J Clin Oncol 7: 445–449, 1989.
- 16 Moll UM, Ostermeyer AG, Ahomadegbe J-C, Mathieu M-C, Riou G: p53 mediated tumor cell response to chemotherapeutic DNA damage: A preliminary study in matched pairs of breast cancer biopsies. Hum Pathol 26: 1293–1301, 1995.
- 17 Müller P, Weckermann D, Riethmüller G, Schlimok G: Detection of genetic alterations in micrometastatic cells in bone marrow of cancer patients by fluorescence in situ hybridization. Cancer Genet Cytogenet 88: 8–16, 1996.
- 18
Müller P,
Carroll P,
Bowers E,
Moore IID,
Cher M,
Presti J,
Wessmann M,
Pallavicini MG:
Quantitation and molecular cytogenetic characterization of epithelial cells in marrow aspirates from patients with prostate cancer.
Cancer
83:
538–546,
1998.
10.1002/(SICI)1097-0142(19980801)83:3<538::AID-CNCR23>3.0.CO;2-W PubMed Web of Science® Google Scholar
- 19 Osborne MP, Rosen PP: Detection and management of bone marrow micrometastases in breast cancer. Oncology 8: 25–31, 1994.
- 20 Pantel K, Schlimok G, Kutter D, Schaller G, Genz T, Wiebecke B, Backmann R, Funke I, Riethmüller G: Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res 51: 4712–4715, 1991.
- 21 Pantel K, Schlimok G, Angstwurm M, Weckermann D, Schmaus W, Gath H, Passlick B, Izbicki JR, Riethmüller G: Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother 3: 165–173, 1994.
- 22 Pantel K, Izbicki J, Passlik B, Angstwurm M, Häussinger K, Thetter O, Riethmüller G: Frequency and prognostic significance of isolated tumor cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet 347: 649–653, 1996.
- 23 Passos-Coelho JL, Ross AA, Kahn DJ, Moss TJ, Davis JM, Huelskamp A-M, Noga S-J, Davidson NE, Kennedy MJ: Similar breast cancer cell contamination of single-day peripheral blood progenitor-cell collections obtained after priming withhematopoietic growth factor alone or after cyclophosphamide followed by growth factor. J Clin Oncol 14: 2569–2575, 1996.
- 24 Pinkel D, Straume T, Gray JW: Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization. Proc Natl Acad Sci USA 83: 2934–2938, 1986.
- 25 Price CM, Kanfer EJ, Colman SM, Westwood N, Barrett AJ, Greaves MF: Simultaneous genotypic and immunophenotypic analysis of interphase cells using dual-color fluorescence: A demonstration of lineage involvement in polycythemia vera. Blood 80: 1033–1038, 1992.
- 26 Riesenberg R, Oberneder R, Kriegmair M, Epp M, Bitzer U, Hofstetter A, Braun S, Riethmüller G, Pantel K: Immunocytochemical double staining of cytokeratin and prostate specific antigen in individual prognostic tumor cells. Histochemistry 99: 61–66, 1993
- 27 Ring DB, Clark R, Saxena A: Identity of BCA 200 and c-erbB-2 indicated by reactivity of monoclonal antibodies with recombinanat c-erbB-2. Mol Immunol 28: 915–917, 1991.
- 28 Ross AA, Cooper BW, Lazarus HM, Mackay W, Moss TJ, Ciobanu N, Tallman MS, Kennedy JM, Davidson NE, Sweet D, Winter C, Akard L, Jansen J, Copelan E, Meagher RC, Herzig RH, Klumpp TR, Kahn DG, Warner NE: Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 82: 2605–2610, 1993.
- 29 Ross AA, Layton TJ, Ostrander AB, Passos-Coelho JL, Davis JM, Huelskamp AM, Noga SJ, Davidson NE, Kennedy MJ, Cooper BW, Gerson SL, Lazarus HM, Holland K, Gluck S, Moss TJ, Kaubish A, Vahdat L, Antman K: Comparative analysis of breast cancer contamination in mobilized and nonmobilized hematopoietic grafts. J Hematother 5: 549–552, 1996.
- 30 Schlimok G, Funke I, Holzmann B. Göttlinger G, Schmidt G, Häuser H, Swierkot S, Warnecke HH, Schneider B, Koprowski H, Riethmüller G: Micrometastatic cancer cells in bone marrow: In vitro detection with anticytokeratin and in vivo labeling with anti-17–1A monoclonal antibodies. Proc Natl Acad Sci USA 84: 8672–8676, 1987.
- 31 Schlimok G, Lindemann F, Holzmann K, Witte J, Renner D, Riethmüller G: Prognostic significance of disseminated tumor cells detected in bone marrow of patients with breast and colorectal cancer: A multivariate analysis. Proc Am Soc Clin Oncol 11: 102 (abstr), 1992.
- 32 Schulze R, Schulze M, Wischnik A, Ehnle S, Doukas K, Behr W, Ehret W, Schlimok G: Tumor cell contamination of peripheral blood stem cell transplants and bone marrow in high risk breast cancer patients. Bone Marrow Transpl 19: 1223–1228, 1997.
- 33
Seshadri R,
Leong AS-Y,
Mc-Caul K,
Firgaira FA,
Setlur V,
Horsfall DJ:
Relationship between p53 gene abnormalities and other tumour characteristics in breast cancer prognosis.
Int J Cancer
69:
135–141,
1996.
10.1002/(SICI)1097-0215(19960422)69:2<135::AID-IJC12>3.0.CO;2-8 CAS PubMed Web of Science® Google Scholar
- 34 Shimamura A, Fisher DE: p53 in life and death. Clin Cancer Res: 435–440, 1996.
- 35 Speel EJM, Herbergs J, Ramaeker FCS, Hopman AHN: Combined immunocytochemistry and fluorescence in situ hybridization for simultaneous tricolor detection of cell cycle, genomic and phenotypic parameters of tumor cells. J Histochem Cytochem 42: 961–966, 1994.
- 36 Stosiek P, Kasper M, Karsten U, Goertchen R: Detection of cancer metastases in regional lymph nodes: Comparative histological and immuno- histological investigations with the broad-range anticytokeratin monoclonal antibody A45-B/B3. Neoplasma 38: 43–47, 1991.
- 37 Weber-Matthiesen K, Deerberg J, Boetsch M, Grote W, Schlegelberger B: Numerical chromosome aberrations are present within the CD301 Hodgkin and Reed-Sternberg cells in 100% of analysed cases of Hodgkin's disease. Blood 86: 1464–1468, 1995.
